VCANBIO(SH:600645) Shang Hai Zheng Quan Bao·2025-07-29 17:34Group 1 - The company held its 20th temporary board meeting on July 28, 2025, where it approved the acquisition of 25% equity in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. [1][12] - The acquisition was approved with 7 votes in favor, 0 against, and 0 abstentions, and the related directors recused themselves from the vote [2][5][12] - The transaction is classified as a related party transaction due to the controlling relationship between the parties involved [8][14] Group 2 - The total assessed value of 100% equity in Shanghai Zhongyuan Jisheng is RMB 15.2783 million, with the agreed transfer price for the 25% stake set at RMB 3,819,575 [9][10][20] - The transaction does not constitute a major asset restructuring and does not require shareholder approval [9][13] - The company aims to enhance operational efficiency and increase resource investment in adult health cell storage business through this acquisition [30][31] Group 3 - The company plans to establish its East China headquarters in Shanghai and has signed a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd. [34][36] - The total rent for the leased property is RMB 12,239,910, with a rental period from August 1, 2025, to July 31, 2028 [35][36] - The rental price is set at RMB 6 per day per square meter, with options for payment that include discounts for upfront payments [36][49] Group 4 - The lease agreement includes provisions for shared use of certain areas and specifies that the company will not incur additional business dependencies on related parties [56][57] - The company’s independent directors have reviewed and approved the lease agreement, confirming that it aligns with the company's strategic planning and does not harm shareholder interests [57][58]